Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

The Prognostic Role of Corticosteroid Administration in Hospitalized Patients with Severe COVID-19: A Cross-sectional Study

Author(s): Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Ali Moradi, Mohammad Moein Vakilzadeh, Zahra Mazloum Khorasani, Mahmoud Ghavi* and Amirhossein Sahebkar*

Volume 17, Issue 2, 2023

Published on: 05 October, 2023

Page: [152 - 157] Pages: 6

DOI: 10.2174/0127722708245041230921064257

Price: $65

Abstract

Background and Objective: The COVID-19 pandemic is a recent global issue with no established consensus on treatments. Therefore, the aim of this study was to assess the impact of corticosteroid (CS) pulses on the prognosis of COVID-19 patients admitted to hospitals.

Methods: In this retrospective single-center cross-sectional study, we used hospital records of all consecutive patients aged 18 years or older admitted to the hospital from July 23rd to September 23rd, 2021. All patients included in the study had confirmed SARS-CoV-2 infection using polymerase chain reaction (PCR) testing and required hospitalization. Demographic and clinical information, as well as patient outcomes, were collected. Treatment details, including the type(s), cumulative doses, and duration of administered corticosteroids, were also recorded. CS pulse therapy was defined as the daily administration of 24 mg or more of dexamethasone or its equivalents.

Results: A total of 500 patients with COVID-19 were included in this study, comprising 122 patients who received CS pulse therapy and 378 patients who did not. A higher mortality rate was observed in patients receiving CS pulse therapy (42.6%) compared to the other group (28%) (p =0.04). Additionally, logistic regression analysis showed an increased mortality risk in patients receiving CS pulse therapy in the crude model (OR=1.54, 95% CI: 1.01-2.27, p <0.01). However, after adjusting for confounding factors, such as mechanical ventilation and ICU admission, the results were reversed (OR=0.21, 95% CI: 0.07-0.62, p <0.01).

Conclusion: In the findings of the current study, treatment with CS pulses was shown to significantly enhance recovery in patients with non-severe COVID-19.

« Previous Next »
Graphical Abstract

[1]
Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ 2020; 730: 138996.
[http://dx.doi.org/10.1016/j.scitotenv.2020.138996] [PMID: 32371230]
[2]
Ochani R, Asad A, Yasmin F, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med 2021; 29(1): 20-36.
[PMID: 33664170]
[3]
Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(24): 759-65.
[http://dx.doi.org/10.15585/mmwr.mm6924e2] [PMID: 32555134]
[4]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[5]
Pham B, Rios P, Radhakrishnan A, et al. Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review. BMJ Open 2022; 12(6): e045115.
[http://dx.doi.org/10.1136/bmjopen-2020-045115] [PMID: 35947494]
[6]
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384(8): 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[7]
Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A Randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021; 72(9): e373-81.
[http://dx.doi.org/10.1093/cid/ciaa1177] [PMID: 32785710]
[8]
Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA 2020; 324(13): 1317-29.
[http://dx.doi.org/10.1001/jama.2020.17022] [PMID: 32876697]
[9]
Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. JAMA 2020; 324(13): 1298-306.
[http://dx.doi.org/10.1001/jama.2020.16761] [PMID: 32876689]
[10]
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 2020; 324(13): 1307-16.
[http://dx.doi.org/10.1001/jama.2020.17021] [PMID: 32876695]
[11]
Jamaati H, Hashemian SM, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol 2021; 897: 173947.
[http://dx.doi.org/10.1016/j.ejphar.2021.173947] [PMID: 33607104]
[12]
Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ 2020; 369: m2422.
[http://dx.doi.org/10.1136/bmj.m2422] [PMID: 32546467]
[13]
Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 2020; 324(13): 1330-41.
[http://dx.doi.org/10.1001/jama.2020.17023] [PMID: 32876694]
[14]
Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020; 71(16): 2114-20.
[http://dx.doi.org/10.1093/cid/ciaa601] [PMID: 32427279]
[15]
Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016; 15(4): 457-65.
[http://dx.doi.org/10.1517/14740338.2016.1140743] [PMID: 26789102]
[16]
Al-Tawfiq JA, Alhumaid S, Alshukairi AN, et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection 2021; 49(5): 833-53.
[http://dx.doi.org/10.1007/s15010-021-01670-1] [PMID: 34302291]
[17]
Medhi B, Bhattacharyya A, Sarma P, et al. COVID-19–associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol 2021; 53(6): 499-510.
[http://dx.doi.org/10.4103/ijp.ijp_839_21] [PMID: 34975140]
[18]
Mishra Y, Prashar M, Sharma D. Akash, Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr 2021; 15(4): 102196.
[http://dx.doi.org/10.1016/j.dsx.2021.102196] [PMID: 34246939]
[19]
Cui Y, Sun Y, Sun J, et al. Efficacy and safety of corticosteroid use in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Infect Dis Ther 2021; 10(4): 2447-63.
[http://dx.doi.org/10.1007/s40121-021-00518-3] [PMID: 34389970]
[20]
Organization WH. COVID-19 weekly epidemiological update. edition 115. 2022; 2022.
[21]
Katzung B, Masters S, Trevor A. Adrenocorticosteroids and adrenocortical antagonists Basic and clinical pharmacology. (9th ed.). New York: The McGraw Hill Co. 2004; pp. 641-60.
[22]
Asare K. Diagnosis and treatment of adrenal insufficiency in the critically ill patient. Pharmacotherapy 2007; 27(11): 1512-28.
[http://dx.doi.org/10.1592/phco.27.11.1512] [PMID: 17963461]
[23]
Schimmer BP, Funder JW. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Goodman and Gilman’s the pharmacological basis of therapeutics. 2011; pp. 1209-36.
[24]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[25]
Ruiz-Irastorza G, Pijoan JI, Bereciartua E, et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoS One 2020; 15(9): e0239401.
[http://dx.doi.org/10.1371/journal.pone.0239401] [PMID: 32960899]
[26]
Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020; 56(6): 2002808.
[http://dx.doi.org/10.1183/13993003.02808-2020] [PMID: 32943404]
[27]
Rubio JLC. Castillo Juan de Dios Luna Del, Fernández Javier de la Hera, Arrabal EGC, Ruiz MC, Centeno NO. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection. Med Clin (Barc) 2020; 155(4): 159-61.
[28]
Zhan Y, Shang J, Gu Y, Huang Q, Xie J. Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis. J Med Virol 2021; 93(7): 4292-302.
[http://dx.doi.org/10.1002/jmv.26914] [PMID: 33666250]
[29]
Maskin LP, Bonelli I, Olarte GL, et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: A multicenter, randomized open-label clinical trial. J Intensive Care Med 2022; 37(4): 491-9.
[http://dx.doi.org/10.1177/08850666211066799] [PMID: 34898320]
[30]
Bonakdaran S, Layegh P, Hasani S, et al. The prognostic role of metabolic and endocrine parameters for the clinical severity of COVID-19. Dis Markers 2022; 2022: 5106342.
[http://dx.doi.org/10.1155/2022/5106342]
[31]
Goshayeshi L, Akbari Rad M, Bergquist R, Allahyari A, Hashemzadeh K, Hoseini B. Demographic and clinical characteristics of severe Covid-19 infections: a cross-sectional study from Mashhad University of Medical Sciences, Iran. BMC Infect Dis 2021; 21(1): 656.
[http://dx.doi.org/10.1186/s12879-021-06363-6] [PMID: 34233638]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy